Mostrar Notícias:

SEPRPrincipaisÚltima HoraBovespa - Brasil

 Ver notícias de outros activos

Pesquisa de notícias relativas à acção Sepracor Inc. (ordenadas pela data):

Desloratadine Market Report 2018 Global: Top Manufacturers ... theaerospacenews.com Global Desloratadine Market research report covers the present market size of the Desloratadine market and its progress rates based on history data along with ... e mais »

Allergy Treatment Market Rugged Expansion Foreseen by 2026 Digital Journal ... market are Allergy therapeutics, Allergopharma, Allergon AB, Alerpharma S.A, Allergan, Inc., Genentech Inc., Schering-Plough Corporation, McNeil Consumer Healthcare, Collegium Pharmaceutical, Inc., Meda Pharmaceuticals, Inc, Sepracor, Inc. and ... e mais »

LANews By Abhishek Budholiya (press release) (blog)

Allergy Treatment Market is Expecting Worldwide Growth by 2026 LANews By Abhishek Budholiya (press release) (blog) ... treatment market are Allergy therapeutics, Allergopharma, Allergon AB, Alerpharma S.A, Allergan, Inc., Genentech Inc., Schering-Plough Corporation, McNeil Consumer Healthcare, Collegium Pharmaceutical, Inc., Meda Pharmaceuticals, Inc, Sepracor, Inc. e mais »

Desloratadine Market Research Report Includes Market Dynamics 2018: Opportunities, Risk And Driving Force ... Stock Analysis Desloratadine Market Segment by Manufacturers includes: Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, ... e mais »

Global Desloratadine Market 2018 Research Report Analysis By Emerging Trends, Growth Drivers, Outlook And ... managementjournal24.com Desloratadine Market Segment by Manufacturers includes: Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, ... e mais »

Positive Newspaper

Global Desloratadine Market Demand 2018- Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan ... Positive Newspaper Some of the well-known players in the market are Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, Nanjing ... e mais »

Desloratadine Market Drivers, Research Findings, Analyst Introduction, Data Source, Methodology till 2023 Healthcare Sector Some of the key companies in the Global Desloratadine market include: Pfizer, Teva, Wante Pharmaceutical?, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, ... United States Desloratadine Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2025The Newsman todos os 3 artigos de notícias »

Worldwide Desloratadine Market Report Global: Top Manufacturers Revenue, Type And Applications Estimate To 2023 theautomarketnews.com Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, Nanjing Hicin Pharmaceutical, Hairui Pharmaceutical, Hainan ...

BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph ... PR Newswire (press release) NEW YORK and PETACH TIKVAH, Israel, June 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Joseph ... Dr ... e mais »

BSA bureau (press release)

Sumitomo Dainippon appoints Nomura as President & CEO BSA bureau (press release) In 2010, Sunovion (formerly Sepracor Inc.), was acquired by Sumitomo Dainippon. Nomura took the position of the Vice Chair, Executive Vice President and CFO, Sunovion Pharmaceuticals Inc. in 2012. Following 2014, he became associated with the ... e mais »

Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer GlobeNewswire (press release) Mr. Hastings also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. During his tenure at ArQule, he played an important role in ArQule's transition into a drug discovery and development organization, and in two ...

Global Desloratadine Market Company Basic Information, Manufacturing Base, Sales Area and Its Competitors with ... The Newsman Pfizer Teva Wante Pharmaceutical Novartis India Limited Mylan Sepracor Sandoz Apollo Pharmaceuticals GSK Mayne Pharma Inc Abhilasha Pharma Pvt Abbott Takeda Schering-Plough Nanjing Hicin Pharmaceutical Hairui Pharmaceutical Hainan Poly ... e mais »

Business Wire (press release)

Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary Business Wire (press release) Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. (now known as Sunovion Pharmaceuticals ... e mais »

Business Wire (press release)

BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, MD, as ... Business Wire (press release) Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax Technologies Corp., Regeneron Pharmaceuticals, Sepracor Inc. and PDL Biopharma. e mais »

Business Wire (press release)

Entasis Therapeutics Appoints David C. Hastings to Board of Directors Business Wire (press release) BUSINESS WIRE)--Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of David C. Hastings to the company's Board of ...

Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer Business Wire (press release) Prior to joining Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility including Vice President ... e mais »

Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, MD to its Board of Directors GlobeNewswire (press release) In addition to his experience at Pfizer, Dr. Harrigan previously served as President & CEO of Karuna Pharmaceuticals, and in senior clinical leadership positions at Neurogen Corp. and Sepracor, Inc. Prior to entering the pharmaceutical industry in 1990 ... e mais »

Form S-1 Spero Therapeutics, Inc. StreetInsider.com Unless the context otherwise requires or as otherwise noted, we use the terms ?Spero Therapeutics,? ?company,? ?we,? ?us? and ?our? in this prospectus to refer to Spero Therapeutics, Inc. and its subsidiaries taken as a whole. Overview. We are a multi ... e mais »

Business Wire (press release)

Rodin Therapeutics Expands Leadership Team, Adding Extensive Experience in Clinical and Business Development Business Wire (press release) She then joined Sunovion Pharmaceuticals, Inc. (formerly Sepracor), moving through positions of increasing responsibility into the role of vice president for corporate development and licensing. Sullivan played an instrumental role in the company's ...

Desloratadine Market Analysis 2018-2025: Top Vendors Like Pfizer, Teva, Mylan, Sepracor, Sandoz, Abbott, Takeda Digital Journal New York, NY -- (SBWIRE) -- 06/11/2018 -- The Study Paper on Top key vendors in Desloratadine Market includes are Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, ...

Spero Announces Appointment of David P. Southwell to its Board of Directors GlobeNewswire (press release) 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced ... e mais »

The Boston Globe

Japanese executives ponder investing in Mass. The Boston Globe They visited a giant laboratory in Cambridge shared by emerging biotech companies and walked the life sciences mecca that is Kendall Square. They met with government officials who want to lure foreign companies to Massachusetts. They even saw the ...

Sunovion Pharmaceuticals Inc. Announces Company Name Change Business Wire (press release) MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion), formerly Sepracor Inc. (Sepracor), announced today that it has formally changed its name. The change occurs on approximately the one year anniversary of the ... e mais »

Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors Business Wire (press release) From 2007-2010, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc., where he was responsible for the company's legal and government affairs departments and Corporate Secretarial function until its ... e mais »

Dainippon Sumitomo Pharma to Acquire Sepracor for US $23.00 Per Share in an All-Cash Tender Offer Valued at ... FierceBiotech BUSINESS WIRE)--Dainippon Sumitomo Pharma Co., Ltd. ("DSP", TSE: 4506) and Sepracor Inc. ("Sepracor", Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately ... Drugmaker Sepracor Accepts $2.6B Buyout Offer from Japan's DainipponXconomy todos os 485 artigos de notícias »

Minerva Neurosciences Names Richard Russell President GlobeNewswire (press release) 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell ... e mais »

Business Wire (press release)

Flex Pharma Reports Year End 2017 Financial Results Business Wire (press release) BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe ... e mais »

Sleep Disturbances in Elderly Patients: June 2018 Healio Sponsorship Statement: This CME activity is jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals. ... Faculty members report the following financial relationships: Andrew A. Nierenberg, MD, has disclosed the following ...

TheChronicleHerald.ca

PEI's BioVectra buys former Sepracor plant in Windsor TheChronicleHerald.ca A Charlottetown drug manufacturer has acquired a mothballed Windsor pharmaceutical plant and plans to reopen the facility in early 2016. BioVectra Inc. purchased the former Sepracor Canada (Nova Scotia) Ltd. facility in May. The Sepracor operation ... e mais »

GlobeNewswire (press release)

VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors GlobeNewswire (press release) ... 2003 Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. Prior to his employment with ArQule, Mr. Hastings was Vice President and Corporate Controller at Genzyme Inc., and Director of Finance at Sepracor ... e mais »